Tiziana Life Sciences Ltd
Tiziana Life Sciences Ltd
Your view on TLSA
Overview
What the company does, where it operates, and who runs it.
About Tiziana Life Sciences Ltd
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Ivor R. Elrifi
- Headquarters
- 55 Park Lane, London, GB
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Ivor R. Elrifi
- Headquarters
- 55 Park Lane, London, GB
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology.
The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.
It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients.
The company was incorporated in 1998 and is headquatered in London, the United Kingdom.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Tiziana Life Sciences Ltd, and the rating behind it. TLSA last traded at $0.96; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Tiziana Life Sciences Ltd. Starting points for Tiziana Life Sciences Ltd: EPS -$0.38, beta 0.46 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Tiziana Life Sciences Ltd. Tiziana Life Sciences Ltd does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Tiziana Life Sciences Ltd. Trailing twelve-month EPS for Tiziana Life Sciences Ltd stands at -$0.38. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Tiziana Life Sciences Ltd. Tiziana Life Sciences Ltd has reported as a listed company since 2018. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Tiziana Life Sciences Ltd valued side by side against its closest peers. Tiziana Life Sciences Ltd is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Tiziana Life Sciences Ltd, and how their positions are changing. At a $61.1M market value, institutional positions materially move Tiziana Life Sciences Ltd's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Tiziana Life Sciences Ltd executives and directors. Shares of Tiziana Life Sciences Ltd have traded between $0.63 and $2.60 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Tiziana Life Sciences Ltd. Tiziana Life Sciences Ltd is a $61.1M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Tiziana Life Sciences Ltd. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Tiziana Life Sciences Ltd. Coverage tracks Tiziana Life Sciences Ltd within Biotechnology (Healthcare). Press releases and market coverage, newest first.